At the level of individual MACE components, GLP-1 RAs also reduced CV mortality (by 13%, P = 0.016), nonfatal stroke (by 16%, P = 0.007), and nonfatal MI (by 9%, but statistically non-significant). This evidence concerns the gene GCG and Stroke.